NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free IMUX Stock Alerts $1.24 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.2950-Day Range$1.18▼$1.5352-Week Range$0.95▼$3.11Volume129,677 shsAverage Volume849,295 shsMarket Capitalization$111.51 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immunic alerts: Email Address Immunic MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside585.5% Upside$8.50 Price TargetShort InterestHealthy3.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector656th out of 909 stocksPharmaceutical Preparations Industry297th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunic has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.37% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunic has recently increased by 22.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMUX. Previous Next 2.3 News and Social Media Coverage News SentimentImmunic has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immunic this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Immunic to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunic are expected to remain at ($0.99) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Immunic Stock (NASDAQ:IMUX)Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Read More IMUX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUX Stock News HeadlinesApril 21, 2024 | americanbankingnews.comImmunic (NASDAQ:IMUX) Rating Increased to Hold at StockNews.comApril 19, 2024 | finance.yahoo.comImmunic, Inc. (IMUX)April 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)April 12, 2024 | morningstar.comImmunic Inc IMUXApril 5, 2024 | msn.comBrookline Capital starts Immunic at buy, cites MS drug candidateApril 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)April 4, 2024 | finance.yahoo.comWith 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investorsApril 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 4, 2024 | finance.yahoo.comImmunic to Host MS R&D Day and Participate in Investor Conferences in AprilMarch 20, 2024 | marketwatch.comImmunic Gets Allowance for Vidofludimus Calcium Patent ApplicationMarch 20, 2024 | proactiveinvestors.comImmunic granted patent for specific polymorph of vidofludimus calcium in USMarch 20, 2024 | prnewswire.comImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesMarch 18, 2024 | proactiveinvestors.comImmunic CMO discusses complexities of multiple sclerosis to mark MS Awareness MonthMarch 7, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MarchFebruary 29, 2024 | proactiveinvestors.comImmunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trialsFebruary 29, 2024 | prnewswire.comImmunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024February 26, 2024 | markets.businessinsider.comHold Rating on Immunic: Balancing Long-Term Potential Against Short-Term UncertaintiesFebruary 23, 2024 | finance.yahoo.comImmunic Inc (IMUX) Reports Year-End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial RunwayFebruary 22, 2024 | proactiveinvestors.comImmunic expects financial stability through 2025 as MS clinical programs advanceFebruary 22, 2024 | proactiveinvestors.comImmunic reports successful 2023 and prepares for key 2025 milestonesFebruary 22, 2024 | finance.yahoo.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 22, 2024 | prnewswire.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 21, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX) Dividends: History, Yield and DatesFebruary 21, 2024 | benzinga.comImmunic's Earnings OutlookSee More Headlines Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees77Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+585.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.44% Return on Assets-117.42% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio2.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.94Miscellaneous Outstanding Shares89,930,000Free Float87,501,000Market Cap$111.51 million OptionableOptionable Beta2.07 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Duane D. Nash J.D. (Age 53)M.B.A., M.D., Executive Chairman Comp: $433.4kDr. Daniel Vitt Ph.D. (Age 56)CEO, President & Director Comp: $728.4kMr. Glenn Whaley CPA (Age 56)Chief Financial Officer Comp: $522.21kDr. Andreas Muehler M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $599.57kDr. Hella Kohlhof (Age 51)Chief Scientific Officer Jessica BreuHead of Investor Relations & CommunicationsMr. Inderpal Singh (Age 58)General Counsel Mr. Patrick Walsh (Age 41)Chief Business Officer More ExecutivesKey CompetitorsCartesian TherapeuticsNASDAQ:RNACCytomX TherapeuticsNASDAQ:CTMXOptiNoseNASDAQ:OPTNCyteir TherapeuticsNASDAQ:CYTTSeres TherapeuticsNASDAQ:MCRBView All CompetitorsInsiders & InstitutionsSummit Trail Advisors LLCBought 18,600 shares on 4/23/2024Ownership: 0.021%Sierra Summit Advisors LLCBought 324,829 shares on 2/22/2024Ownership: 0.719%Gratus Capital LLCBought 254,999 shares on 2/7/2024Ownership: 4.300%Glenn WhaleyBought 5,000 shares on 5/15/2023Total: $8,750.00 ($1.75/share)View All Insider TransactionsView All Institutional Transactions IMUX Stock Analysis - Frequently Asked Questions Should I buy or sell Immunic stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMUX shares. View IMUX analyst ratings or view top-rated stocks. What is Immunic's stock price target for 2024? 2 equities research analysts have issued 1-year target prices for Immunic's shares. Their IMUX share price targets range from $7.00 to $10.00. On average, they predict the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 585.5% from the stock's current price. View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts. How have IMUX shares performed in 2024? Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX shares have decreased by 17.3% and is now trading at $1.24. View the best growth stocks for 2024 here. Are investors shorting Immunic? Immunic saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,030,000 shares, an increase of 22.7% from the March 15th total of 2,470,000 shares. Based on an average trading volume of 976,400 shares, the days-to-cover ratio is currently 3.1 days. View Immunic's Short Interest. When is Immunic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IMUX earnings forecast. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.03. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Who are Immunic's major shareholders? Immunic's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Summit Trail Advisors LLC (0.02%). Insiders that own company stock include Andreas Muehler, Daniel Vitt, Duane Nash, Glenn Whaley and Joerg Neermann. View institutional ownership trends. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMUX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
